After weeks of anticipation, U.S. Treasury officials last night .  to thwart U.S. companies from moving their legal headquarters to lower-tax countries. The move came amid growing concern over so-called tax inversions that effectively reduce federal revenue and have been increasingly popular in the pharmaceutical industry.. The changes will make it harder for companies that invert to use cash that has accumulated abroad. As a result, AbbVie’s $54 billion deal to buy Shire may not look so attractive now, Medtronic may try to renegotiate its $43 billion deal for Covidien and Mylan Laboratories’ plan to buy European assets from Abbott Laboratories may be at risk, analysts say.